| | |
CA IX positive
|
CA IX negative
|
χ2/P value
|
|---|
|
All
| |
151 (16%)
|
794 (84%)
| |
|
Protocol
|
Pre (DBCG82b)
|
89 (59%)
|
447 (56%)
|
0.5
|
| |
Post (DBCG82c)
|
62 (41%)
|
347 (44%)
| |
|
Tumour size (mm)
|
<21
|
48 (32%)
|
289 (36%)
|
0.5
|
| |
21 to 50
|
81 (54%)
|
393 (49%)
| |
| |
>50
|
22 (15%)
|
112 (14%)
| |
|
Positive nodes
|
None
|
6 (3%)
|
50 (6%)
|
0.5
|
| |
1 to 3
|
70 (46%)
|
346 (44%)
| |
| |
>3
|
75 (50%)
|
398 (50%)
| |
|
Histopathology
|
Ductal
|
133 (88%)
|
680 (86%)
|
0.4
|
| |
Nonductal
|
18 (12%)
|
114 (14%)
| |
|
Malignancy grade
|
Grade 1
|
18 (12%)
|
166 (21%)
|
P < 0.0001
|
| |
Grade 2
|
56 (37%)
|
357 (45%)
| |
| |
Grade 3
|
59 (39%)
|
157 (20%)
| |
| |
Nonductal
|
18 (12%)
|
114 (14%)
| |
|
ER
|
Positive
|
50 (33%)
|
581 (73%)
|
P < 0.0001
|
| |
Negative
|
101 (67%)
|
213 (27%)
| |
|
PgR
|
Positive
|
47 (31%)
|
506 (64%)
|
P < 0.0001
|
| |
Negative
|
104 (69%)
|
288 (36%)
| |
|
HER2
|
Negative
|
101 (33%)
|
636 (80%)
|
P < 0.0001
|
| |
Positive
|
50 (67%)
|
636 (80%)
| |
- Shown is the distribution of various clinicopathological parameters among carbonic anhydrase (CA) IX positive and CA IX negative high-risk breast cancer patients randomized to receive or not receive postmastectomy radiotherapy. ER, oestrogen receptor; HER, human epidermal growth factor; PgR, progesterone receptor.
